• Immunohistochemistry analysis of paraffin-embedded human brain, using Ephrin B1/B2/B3 (Phospho-Tyr324) Antibody. The picture on the right is blocked with the phospho peptide.
  • Western blot analysis of lysates from K562 cells treated with serum 20% 15', using Ephrin B1/B2/B3 (Phospho-Tyr324) Antibody. The lane on the right is blocked with the phospho peptide.
  • Western blot analysis of JK cells using Phospho-Ephrin-B1/2/3 (Y324) Polyclonal Antibody

Anti-Phospho-Ephrin-B1/2/3-Tyr324 antibody (290-339 aa) (STJ90972)

SKU:
STJ90972

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Phospho-Ephrin-B1 and Ephrin-B2 and Ephrin-B3-Tyr324 (290-339 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:20000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: EFNB3
EFNB1
1949
1947
1948
EFNB3_HUMAN
EFNB1_HUMAN
EFNB2_HUMAN
Immunogen Region: 290-339 aa
Specificity: Phospho-Ephrin-B1/2/3 (Y324) Polyclonal Antibody detects endogenous levels of Ephrin-B1/2/3 protein only when phosphorylated at Y324.
Immunogen: The antiserum was produced against synthesized peptide derived from the human Ephrin B1/B2/B3 around the phosphorylation site of Tyr324 at the amino acid range 290-339
Post Translational Modifications Inducible phosphorylation of tyrosine residues in the cytoplasmic domain. Proteolytically processed. The ectodomain is cleaved, probably by a metalloprotease, to produce a membrane-tethered C-terminal fragment. This fragment is then further processed by the gamma-secretase complex to yield a soluble intracellular domain peptide which can translocate to the nucleus. The intracellular domain peptide is highly labile suggesting that it is targeted for degradation by the proteasome.
Function Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binding to Eph receptors residing on adjacent cells leads to contact-dependent bidirectional signaling into neighboring cells. Shows high affinity for the receptor tyrosine kinase EPHB1/ELK. Can also bind EPHB2 and EPHB3. Binds to, and induces collapse of, commissural axons/growth cones in vitro. May play a role in constraining the orientation of longitudinally projecting axons.
Protein Name Ephrin-B1
Efl-3
Elk Ligand
Elk-L
Eph-Related Receptor Tyrosine Kinase Ligand 2
Lerk-2 Cleaved Into - Ephrin-B1 C-Terminal Fragment
Ephrin-B1 Ctf - Ephrin-B1 Intracellular Domain
Ephrin-B1 Icd
Database Links Reactome: R-HSA-2682334
Reactome: R-HSA-3928662
Reactome: R-HSA-3928664
Reactome: R-HSA-3928665
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Membrane Raft
May Recruit Grip1 And Grip2 To Membrane Raft Domains
Ephrin-B1 C-Terminal Fragment: Cell Membrane
Ephrin-B1 Intracellular Domain: Nucleus
Colocalizes With Zhx2 In The Nucleus
Alternative Antibody Names Anti-Ephrin-B1 antibody
Anti-Efl-3 antibody
Anti-Elk Ligand antibody
Anti-Elk-L antibody
Anti-Eph-Related Receptor Tyrosine Kinase Ligand 2 antibody
Anti-Lerk-2 Cleaved Into - Ephrin-B1 C-Terminal Fragment antibody
Anti-Ephrin-B1 Ctf - Ephrin-B1 Intracellular Domain antibody
Anti-Ephrin-B1 Icd antibody
Anti-EFNB1 antibody
Anti-EFL3 antibody
Anti-EPLG2 antibody
Anti-LERK2 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance